Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.44 |
| ▸ | LPL | P06858 | 13/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990010 | 0.90 | LIPG (0.44) | LIPGLPLDGAT1PDK2CA1 | |
| SCHEMBL22389178 | 0.90 | LIPG (0.44) | LIPGLPLDGAT1PDK2CA1 | |
| SCHEMBL26050350 | 0.90 | LIPG (0.44) | LIPGLPLDGAT1PDK2CA1 | |
| SCHEMBL24257889 | 0.90 | LIPG (0.44) | LIPGLPLDGAT1PDK2CA1 | |
| SCHEMBL26050388 | 0.90 | LIPG (0.44) | LIPGLPLDGAT1PDK2CA1 | |
| SCHEMBL20233453 | 0.89 | LIPG (0.50) | LIPGLPLDGAT1CA1CA2 | |
| SCHEMBL20233449 | 0.88 | LPL (0.48) | LIPGLPLPRMT5WDR77PDK2 | |
| SCHEMBL21031685 | 0.85 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL13103886 | 0.85 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL22990007 | 0.85 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022229234-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-11-03 | — | — | WO | disclosed |